Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$0.84 USD
+0.09 (11.85%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $0.79 -0.05 (-5.95%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Biofrontera Inc. [BFRI]
Reports for Purchase
Showing records 1 - 20 ( 66 total )
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves Use of Up To 3 Tubes of Ameluz Per Treatment, Versus 1 Tube
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Opportunities Conference in NYC on October 9, 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 9, 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
2Q24: Still Expecting 20% YoY Annual Revenue Growth
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Launches FDA-Approved RhodoLED XL Red Light Source Lamp
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Sales Headwind From Change Healthcare Cybersecurity Breach Now Over
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Renegotiates Better Ameluz Terms, Ameluz sNDA PDUFA Set For 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Renegotiates Better Ameluz Terms, Adds $15.5M Cash, Ameluz sNDA PDUFA Set
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
3Q23: 25% Y/Y Revenue Growth For 2023, Cash Flow Positivity In Mid-2025
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Preannounced 3Q23 Revenue, Kept 2023 Guidance, New Ameluz Formulation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Safety Trial With 3 Ameluz Tubes Succeeds, Expecting 2024 Label Expansion
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J